多发性骨髓瘤的临床特征及疗效分析

目的 探讨多发性骨髓瘤的临床特征及不同方案的疗效.方法 回顾性分析2006年2月- 2010年8月110例多发性骨髓瘤的临床特征及治疗情况,对不同方案的疗效进行比较.结果 110例患者中Ⅲ期73例,40例伴发有基础疾病；24例接受MP方案,部分缓解10例,无变化1例,疾病进展8例,总有效率41.7%；其余86例接受...

Analysis of Characteristics and Clinical Outcomes of Multiple Myeloma

Objective To analyze the clinical characteristics and clinical outcomes of patients with multiple myeloma treated with different regimens. Methods We retrospectively analyzed the clinical characteristics and treatments of 110 patients with multiple myeloma treated between February 2006 and August 2010, and compared the clinical outcomes of different treatment regimens. Results Seventy-three out of the 110 patients were at stage Ⅲ, and 40 patients had one or two more fundamental diseases. Twenty-two patients received MP regimen, among whom 10 gained partial alleviation, 1 had no change and 8 were aggravated with a total effective rate of 41.7%. Another 86 cases received combination chemotherapy, and among them, 18 gained complete alleviation, 17 attained partial alleviation, 30 achieved mild alleviation, 17 had no change, and 4 were aggravated with a total effective rate of 40. 7%. In terms of the total effective rate, there was no statistical difference between these two groups. PAD-treated group had a highest effective rate of 62.50%. The median survival time for all the patients was 32. 6 months; 3 year survival rate was 34. 50%. For patients treated with thalidomide, the total effective rate and 3-year survival rate were 35.8% and 36.5 % respectively, while for patients treated with bortezomib, the effective rate was 75 %. Conclusions Patients with multiple myeloma at a late stage complicated with fundamental diseases can develop infections after chemotherapy. Total effective rate of combination chemotherapy is higher than that of MP treatment, but survival rate of the two treatments have no statistical difference. The effective rate can be increased after the using of novel agents such as thalidomide and bortezomib.